Organogenesis Holdings Inc. reported net revenue of $86.7 million for the first quarter of 2025, a 21% decrease compared to $110.0 million in Q1 2024. This decline was primarily driven by a 23% decrease in Advanced Wound Care product revenue, partially offset by an 11% increase in Surgical & Sports Medicine revenue.
The company posted a net loss of $18.8 million, or $(0.17) per share, for the quarter, a significant increase from a net loss of $2.1 million in the prior year. Adjusted EBITDA also shifted to a loss of $(12.5) million, compared to an income of $2.6 million in Q1 2024.
While Organogenesis reaffirmed its full-year 2025 revenue guidance of $480 million to $510 million, it updated its profitability guidance, projecting a GAAP net loss between $(25.0) million and $(3.0) million and Adjusted EBITDA between $10.0 million and $30.0 million. The company confirmed that all patients are expected to complete the second Phase 3 ReNu study by the end of Q2 2025, with BLA submission on track by year-end.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.